Data sourced from ClinicalTrials.gov (NIH registry) Updated weekly IRB-supervised studies only
Home/MI/Muskegon
Updated August 2026 from ClinicalTrials.gov

Paid Clinical Trials in Muskegon, MI

Studies commonly pay $75 to $4,500 per completed study

61 clinical trials are currently recruiting participants within 30 miles of Muskegon. Listings below come straight from the official NIH registry, alongside the area's top-rated research centers with real Google reviews.

61studies recruiting
3+research centers nearby
2condition categories
Live from the NIH registry

Studies recruiting near Muskegon right now

Top 25 of 61 recruiting studies, sorted by proximity — each links to its official registry page

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

Mesothelioma, Non Small Cell Lung Cancer Phase 1 Interventional 336 participants sought
Cancer and Hematology Centers of Western Michigan — Norton Shores, Michigan (4.1 mi) · Sponsor: Bristol-Myers Squibb
See eligibility & contact on ClinicalTrials.gov (NCT05245500)

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 Phase 3 Interventional 1,524 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: Alliance for Clinical Trials in Oncology
See eligibility & contact on ClinicalTrials.gov (NCT06876714)

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Phase 3 Interventional 247 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: National Cancer Institute (NCI)
See eligibility & contact on ClinicalTrials.gov (NCT04269902)

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma Phase 3 Interventional 360 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: National Cancer Institute (NCI)
See eligibility & contact on ClinicalTrials.gov (NCT05256225)

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma Phase 2 Interventional 396 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: SWOG Cancer Research Network
See eligibility & contact on ClinicalTrials.gov (NCT05633615)

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8 Phase 3 Interventional 306 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: National Cancer Institute (NCI)
See eligibility & contact on ClinicalTrials.gov (NCT06498635)

Project: Every Child for Younger Patients With Cancer

Adrenal Gland Pheochromocytoma, Carcinoma In Situ N/A Observational 75,000 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: Children's Oncology Group
See eligibility & contact on ClinicalTrials.gov (NCT02402244)

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

Intestinal Neoplasms, Gastrointestinal Neoplasms Phase 3 Interventional 800 participants sought
The Cancer & Hematology Centers — Norton Shores, Michigan (4.1 mi) · Sponsor: Pfizer
See eligibility & contact on ClinicalTrials.gov (NCT07222800)

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma Phase 3 Interventional 1,450 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: ECOG-ACRIN Cancer Research Group
See eligibility & contact on ClinicalTrials.gov (NCT04566328)

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma Phase 3 Interventional 62 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: Children's Oncology Group
See eligibility & contact on ClinicalTrials.gov (NCT05235165)

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

Pancreatic Carcinoma, Pancreatic Neoplasm Phase 3 Interventional 274 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: SWOG Cancer Research Network
See eligibility & contact on ClinicalTrials.gov (NCT06807437)

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Stage I Breast Cancer Phase 3 Interventional 1,670 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: NRG Oncology
See eligibility & contact on ClinicalTrials.gov (NCT04852887)

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma Phase 3 Interventional 255 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: National Cancer Institute (NCI)
See eligibility & contact on ClinicalTrials.gov (NCT07198074)

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 Phase 3 Interventional 3,680 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: National Cancer Institute (NCI)
See eligibility & contact on ClinicalTrials.gov (NCT06058377)

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8 Phase 2 Interventional 112 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: SWOG Cancer Research Network
See eligibility & contact on ClinicalTrials.gov (NCT04511013)

Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum N/A Interventional 9,500 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: NRG Oncology
See eligibility & contact on ClinicalTrials.gov (NCT05080673)

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers

Pancreatic Neoplasm N/A Observational 770 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: ECOG-ACRIN Cancer Research Group
See eligibility & contact on ClinicalTrials.gov (NCT04239573)

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma Phase 2, Phase 3 Interventional 992 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: National Cancer Institute (NCI)
See eligibility & contact on ClinicalTrials.gov (NCT05987241)

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8 Phase 2 Interventional 2,900 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: National Cancer Institute (NCI)
See eligibility & contact on ClinicalTrials.gov (NCT05564377)

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm Phase 3 Interventional 60 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: Children's Oncology Group
See eligibility & contact on ClinicalTrials.gov (NCT06513962)

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

Metastatic Small Intestinal Adenocarcinoma, Stage III Small Intestinal Adenocarcinoma AJCC v8 Phase 2 Interventional 94 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: SWOG Cancer Research Network
See eligibility & contact on ClinicalTrials.gov (NCT04205968)

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 Phase 3 Interventional 1,875 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: National Cancer Institute (NCI)
See eligibility & contact on ClinicalTrials.gov (NCT05675410)

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia Phase 2 Interventional 461 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: National Cancer Institute (NCI)
See eligibility & contact on ClinicalTrials.gov (NCT04546399)

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma Phase 2 Interventional 189 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: ECOG-ACRIN Cancer Research Group
See eligibility & contact on ClinicalTrials.gov (NCT02734537)
Actively enrolling

Studies you may be able to join near Muskegon

These studies are recruiting through partner research networks. We may be paid a referral fee if you complete their screening form — this never changes what you pay (nothing) or the compensation the study offers you.

Research study for alcohol-related liver damage

Enrolling US adults aged 18 to 70 with alcohol-induced liver damage and a history of heavy drinking. Not open to people with a recent stroke, heart attack, dialysis, or who take blood thinners.

Screening is free and takes a few minutes. Eligibility and any compensation are confirmed by the study team, not by this site.

Check your eligibility

Research study for bladder problems after spinal cord injury

This study is enrolling US adults aged 18 to 75 living with chronic involuntary bladder leakage caused by a spinal cord injury, for research including investigational gene therapy approaches. The study team confirms eligibility and any compensation before enrollment.

Screening is free and takes a few minutes. Eligibility and any compensation are confirmed by the study team, not by this site.

Check your eligibility
Google-rated

Top-rated research centers in Muskegon

Dedicated clinical research sites near you — with their real Google ratings, reviews and contact details

West Michigan Clinical Research Center

2093 Health Dr SW Ste 201, Wyoming, MI 49519
(616) 328-5344

Center for Clinical Research at WMed

★ 5.0 (1 reviews)
1000 Oakland Dr, Kalamazoo, MI 49008
(269) 337-4264
"I would like overnight clinic study paid. Kalamazoo"
— Terri Dee Little, 5★

The Cancer & Hematology Centers

★ 4.8 (368 reviews)
6425 Harvey St, Norton Shores, MI 49444
(231) 737-3469
"When you get checked in for your appointment make sure that if you pay you get a receipt. There was only 1 month I did not pay because of a lost car…"
— Rebecca Provatas, 1★

Clinical trials in Muskegon: what's recruiting

The Muskegon area currently has 61 studies open to new participants, according to the ClinicalTrials.gov registry maintained by the U.S. National Institutes of Health. Among the studies closest to Muskegon, the most active research areas are:

  • Cancer & Oncology22 studies
  • Liver & Kidney2 studies

Every listing shows the study phase, the recruiting site and its distance from Muskegon, and links to the official registry page where eligibility criteria and study contacts are published. Compensation is set by each sponsor: industry surveys report typical payments of $75 to $4,500 per completed study, with short observational studies at the low end and multi-visit or overnight Phase 1 studies at the high end.

How to enroll in a paid study in Muskegon

Start with a study whose condition matches your profile — or a healthy-volunteer study if you have no diagnosis. Contact the research site through the registry page, complete a short phone screen, then attend an in-person screening visit. If you qualify, the study team walks you through the informed consent document, which details every procedure, risk and payment before you commit. You can withdraw at any point, and enrollment is always free.

Muskegon participants can also register with the dedicated research centers listed above — many maintain volunteer databases and call when a matching study opens — or sign up for our email alert below to hear when a new study starts recruiting within 30 miles of your ZIP code.

Frequently asked questions

How much do paid clinical trials in Muskegon pay?
Compensation varies by study length, procedures and overnight stays. Industry surveys report typical payments from $75 to $4,500 per completed study, with simple observational studies at the low end and multi-week inpatient Phase 1 studies at the high end. Each listing's study team will confirm the exact amount before you enroll.
Are clinical trials in Muskegon safe?
Every trial on this page is registered on ClinicalTrials.gov, the official NIH registry, and is overseen by an Institutional Review Board (IRB). Before joining you receive an informed consent document detailing procedures, risks and compensation. Participation is voluntary and you can withdraw at any time.
How do I join a study in Muskegon, MI?
Pick a study that matches your profile, contact the research site (or apply through the study links on this page), pass a phone pre-screen, then attend an in-person screening visit. If you qualify, you review and sign the informed consent and the study begins. The process typically takes 1-3 weeks.
Is compensation for clinical trials taxable?
In the U.S., clinical trial compensation is generally considered taxable income, and research sites may issue a 1099 form for payments above $600 in a year. Reimbursements for travel or meals are typically treated differently. Consult a tax professional for your situation.
Can I be in more than one clinical trial at a time?
Generally no — most studies exclude participants currently enrolled in another trial, and paid Phase 1 studies enforce a washout period (often 30 days or more) between studies. Frequent healthy volunteers in Muskegon typically complete one or two studies per year.

Paid clinical trials near Muskegon

Other metros within reach

Grand Rapids, MI456 Kalamazoo, MI107 South Bend, IN113 Elkhart, IN113 Milwaukee, WI688 Lansing, MI183 Chicago, IL2,445 Round Lake Beach, IL466

By condition

Eligibility and exclusions, condition by condition

Alcoholic Liver Disease in Muskegon Bladder Issues Due To Spinal Cord Injury in Muskegon All conditions

More of MI

South Lyon1,329 Detroit1,190 Ann Arbor1,186 Grand Rapids456 Lansing183 Flint182 Kalamazoo107

New paid studies open every week

Get an email when a new clinical trial starts recruiting within 30 miles of your ZIP code. No spam — only real studies from the NIH registry.

By subscribing you agree to receive study alert emails. Unsubscribe anytime in one click.

Get free trial alerts